Next-generation muscle-directed gene therapy by in silico vector design

Area of Science:

• Molecular Biology
• Gene Therapy
• Muscle Disorders

Background:

• Current gene therapy vectors for muscle disorders show modest clinical advances.
• Next-generation vectors require higher transgene expression for lower, safer doses.

Purpose of the Study:

• To identify novel muscle-specific cis-regulatory modules (CRMs) for enhanced gene expression.
• To improve the efficacy and safety of gene therapy for muscle disorders.

Main Methods:

• Genome-wide data-mining strategy to identify potent muscle-specific CRMs.
• Delivery of CRMs using adeno-associated viral vectors in mouse models.
• Quantification of gene transcription and protein expression levels.

Main Results:

• Identified novel muscle-specific CRMs increase muscle gene transcription up to 400-fold.
• Achieved significantly higher and sustained expression of micro-dystrophin and follistatin.
• Demonstrated robust phenotypic correction in dystrophic mice without apoptosis or immune response.

Conclusions:

• Novel muscle-specific CRMs enhance gene expression for improved muscle-directed gene therapy.
• This approach offers potential for augmented efficacy and safety in treating muscle disorders.
• The findings have broad implications for advancing gene therapy applications.